Dose reduction of coadministered 6-mercaptopurine decreases myelotoxicity following high-dose methotrexate in childhood leukemia (Q44497845)

3 December 2017

Dose reduction of coadministered 6-mercaptopurine decreases myelotoxicity following high-dose methotrexate in childhood leukemia (English)

1 reference

3 December 2017

1 reference

1 reference

1 reference

Nygaard U

1

1 reference

3 December 2017

Schmiegelow K

series ordinal

2

1 reference

3 December 2017

1 July 2003

1 reference

3 December 2017

1 reference

3 December 2017

17

1 reference

3 December 2017

7

1 reference

3 December 2017

1344-1348

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2402990

3 December 2017

0 references

cites work

Improving outcome through two decades in childhood ALL in the Nordic countries: the impact of high-dose methotrexate in the reduction of CNS irradiation. Nordic Society of Pediatric Haematology and Oncology (NOPHO).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

The interaction of 6-mercaptopurine (6-MP) and methotrexate (MTX).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

Intensification of mercaptopurine/methotrexate maintenance chemotherapy may increase the risk of relapse for some children with acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

Polyglutamation of methotrexate. Is methotrexate a prodrug?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

Methylation pharmacogenetics: catechol O-methyltransferase, thiopurine methyltransferase, and histamine N-methyltransferase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

Human thiopurine methyltransferase pharmacogenetics: gene sequence polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

Blast cell methotrexate-polyglutamate accumulation in vivo differs by lineage, ploidy, and methotrexate dose in acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

The clinical pharmacology of methotrexate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

Rescue after intermediate and high-dose methotrexate: background, rationale, and current practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

Effect of methotrexate polyglutamates on thioguanine nucleotide concentrations during continuation therapy of acute lymphoblastic leukemia with mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

Clinical and Pharmacokinetic Risk Factors for High-dose Methotrexate-induced Toxicity in Children with Acute Lymphoblastic Leukemia: A Logistic Regression Analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

Progressive reduction in treatment-related deaths in Medical Research Council childhood lymphoblastic leukaemia trials from 1980 to 1997 (UKALL VIII, X and XI)

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

The effect of methotrexate on the bioavailability of oral 6-mercaptopurine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

7 January 2021

Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

7 January 2021

Risk of relapse in childhood acute lymphoblastic leukemia is related to RBC methotrexate and mercaptopurine metabolites during maintenance chemotherapy. Nordic Society for Pediatric Hematology and Oncology

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

7 January 2021

Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

7 January 2021

Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

7 January 2021

Cytotoxic mechanism of 6-thioguanine: hMutSalpha, the human mismatch binding heterodimer, binds to DNA containing S6-methylthioguanine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

7 January 2021

Mercaptopurine metabolism and risk of relapse in childhood lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

7 January 2021

Prognostic Significance of Methotrexate and 6-Mercaptopurine Dosage During Maintenance Chemotherapy for Childhood Acute Lymphoblastic Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

7 January 2021

Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

7 January 2021

Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2402990

7 January 2021

Identifiers

DOI

10.1038/SJ.LEU.2402990

1 reference

Dimensions Publication ID

3 December 2017

1032604668

0 references

Fatcat ID

release_bpaps3m6fvecdhzu5jsv6s46du

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bpaps3m6fvecdhzu5jsv6s46du

24 November 2022

mapped directly with Wikidata item

1 reference